The trajectory of companies tied to Sildenafil's legacy presents a challenging investment landscape. While the initial success generated substantial gains, generic competition have significantly eroded market share . Investing in connected pharmaceutical companies now requires a careful assessment of proprietary protection , evolving medical trends